Flagship Ventures Fund IV-Rx, L.P. is 10% Owner at Evelo Biosciences, Inc. (EVLO). They have made 3 open-market trades across 2 companies since 2019, most recently 2022-05-27.
CIK 0001590973
2 open-market purchases totalling $105.0M since 2020, against 1 sale. Too few scored purchases to measure a record yet.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.